BioGend Therapeutics Co., Ltd. (6733.TWO)

37.45 -0.15 (-0.40%) At close: 01:30PM CST

BioGend Therapeutics Co., Ltd.

No.3-2, Park Street
4th Floor Nangang District
Taipei 115
Taiwan
886 2 2655 8366
https://www.biogend.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Prof. Te-Li Chen M.D., Ph.D.	Chairman & GM	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.

Description

BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan.

Corporate Governance

BioGend Therapeutics Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.